{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:21:33Z","timestamp":1785525693378,"version":"3.56.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T00:00:00Z","timestamp":1317340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2334-11-261","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T14:20:40Z","timestamp":1317392440000},"source":"Crossref","is-referenced-by-count":81,"title":["Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome"],"prefix":"10.1186","volume":"11","author":[{"given":"Annette C","family":"Reboli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F","family":"Shorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coleman","family":"Rotstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G","family":"Pappas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Kett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haran T","family":"Schlamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene L","family":"Reisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,30]]},"reference":[{"key":"1601_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1086\/514955","volume":"27","author":"AM Rentz","year":"1998","unstructured":"Rentz AM, Halpern MT, Bowden R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998, 27: 781-788. 10.1086\/514955.","journal-title":"Clin Infect Dis"},{"key":"1601_CR2","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1086\/496922","volume":"41","author":"TE Zaoutis","year":"2005","unstructured":"Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C: The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005, 41: 1232-1239. 10.1086\/496922.","journal-title":"Clin Infect Dis"},{"key":"1601_CR3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/376906","volume":"37","author":"PG Pappas","year":"2003","unstructured":"Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE, NIAID Mycoses Study Group: A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003, 37: 634-643. 10.1086\/376906.","journal-title":"Clin Infect Dis"},{"key":"1601_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1128\/CMR.00029-06","volume":"20","author":"MA Pfaller","year":"2007","unstructured":"Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007, 20: 133-163. 10.1128\/CMR.00029-06.","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 1","key":"1601_CR5","doi-asserted-by":"publisher","first-page":"i5","DOI":"10.1093\/jac\/dki218","volume":"56","author":"MD Richardson","year":"2005","unstructured":"Richardson MD: Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005, 56 (Suppl 1): i5-i11.","journal-title":"J Antimicrob Chemother"},{"key":"1601_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"H Wisplinghoff","year":"2004","unstructured":"Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004, 39: 309-317. 10.1086\/421946.","journal-title":"Clin Infect Dis"},{"key":"1601_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jac\/46.3.475","volume":"46","author":"M Cuenca-Estrella","year":"2000","unstructured":"Cuenca-Estrella M, Mellado E, Diaz-Guerra TM, Monzon A, Rodriguez-Tudela JL: Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J Antimicrob Chemother. 2000, 46: 475-477. 10.1093\/jac\/46.3.475.","journal-title":"J Antimicrob Chemother"},{"key":"1601_CR8","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1128\/AAC.47.10.3149-3154.2003","volume":"47","author":"L Ostrosky-Zeichner","year":"2003","unstructured":"Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J, Mangino JE, Lee J: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003, 47: 3149-3154. 10.1128\/AAC.47.10.3149-3154.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"1601_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0732-8893(03)00086-5","volume":"46","author":"F Marco","year":"2003","unstructured":"Marco F, Danes C, Almela M, Jurado A, Mensa J, de la Bellacasa JP, Espasa M, Mart\u00ednez JA, Jim\u00e9nez de Anta MT: Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis. 2003, 46: 259-264. 10.1016\/S0732-8893(03)00086-5.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1601_CR10","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1086\/599039","volume":"48","author":"DL Horn","year":"2009","unstructured":"Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM: Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009, 48: 1695-1703. 10.1086\/599039.","journal-title":"Clin Infect Dis"},{"key":"1601_CR11","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1128\/JCM.39.9.3254-3259.2001","volume":"39","author":"MA Pfaller","year":"2001","unstructured":"Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, Messer SA, SENTRY Participant Group: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol. 2001, 39: 3254-3259. 10.1128\/JCM.39.9.3254-3259.2001.","journal-title":"J Clin Microbiol"},{"key":"1601_CR12","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1128\/JCM.40.4.1298-1302.2002","volume":"40","author":"DJ Diekema","year":"2002","unstructured":"Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, Pfaller MA: Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol. 2002, 40: 1298-1302. 10.1128\/JCM.40.4.1298-1302.2002.","journal-title":"J Clin Microbiol"},{"key":"1601_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1086\/380796","volume":"38","author":"PG Pappas","year":"2004","unstructured":"Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE, Infectious Diseases Society of America: Guidelines for treatment of candidiasis. Clin Infect Dis. 2004, 38: 161-189. 10.1086\/380796.","journal-title":"Clin Infect Dis"},{"key":"1601_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1086\/596757","volume":"48","author":"PG Pappas","year":"2009","unstructured":"Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009, 48: 503-535. 10.1086\/596757.","journal-title":"Clin Infect Dis"},{"key":"1601_CR15","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1128\/AAC.43.9.2148","volume":"43","author":"R Petraitiene","year":"1999","unstructured":"Petraitiene R, Petraitis V, Groll A, Candelario M, Sein T, Bell A, Lyman CA, McMillian CL, Bacher J, Walsh TJ: Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 1999, 43: 2148-2155.","journal-title":"Antimicrob Agents Chemother"},{"key":"1601_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1128\/AAC.45.2.471-479.2001","volume":"45","author":"V Petraitis","year":"2001","unstructured":"Petraitis V, Petraitiene R, Groll AH, Sein T, Schaufele RL, Lyman CA, Francesconi A, Bacher J, Piscitelli SC, Walsh TJ: Dosage-dependent antifungal efficacy of the echinocandin VER-002 (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother. 2001, 45: 471-479. 10.1128\/AAC.45.2.471-479.2001.","journal-title":"Antimicrob Agents Chemother"},{"key":"1601_CR17","doi-asserted-by":"publisher","first-page":"5425","DOI":"10.1128\/JCM.43.11.5425-5427.2005","volume":"43","author":"MA Pfaller","year":"2005","unstructured":"Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ: In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005, 43: 5425-5427. 10.1128\/JCM.43.11.5425-5427.2005.","journal-title":"J Clin Microbiol"},{"key":"1601_CR18","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1128\/JCM.02434-08","volume":"47","author":"SA Messer","year":"2009","unstructured":"Messer SA, Moet GJ, Kirby JT, Jones RN: Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol. 2009, 47: 1942-1946. 10.1128\/JCM.02434-08.","journal-title":"J Clin Microbiol"},{"key":"1601_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/0091270006297227","volume":"47","author":"JA Dowell","year":"2007","unstructured":"Dowell JA, Stogniew M, Krause D, Damle B: Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol. 2007, 47: 461-470. 10.1177\/0091270006297227.","journal-title":"J Clin Pharmacol"},{"key":"1601_CR20","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1177\/0091270005279580","volume":"45","author":"MF Hebert","year":"2005","unstructured":"Hebert MF, Smith HE, Marbury TC, Swan SK, Smith WB, Townsend RW, Buell D, Keirns J, Bekersky I: Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol. 2005, 45: 1145-1152. 10.1177\/0091270005279580.","journal-title":"J Clin Pharmacol"},{"key":"1601_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0149-2918(02)85039-1","volume":"24","author":"EA Stone","year":"2002","unstructured":"Stone EA, Fung HB, Kirschenbaum HL: Caspofungin: an echinocandin antifungal agent. Clin Ther. 2002, 24: 351-377. 10.1016\/S0149-2918(02)85039-1.","journal-title":"Clin Ther"},{"key":"1601_CR22","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1056\/NEJMoa066906","volume":"356","author":"AC Reboli","year":"2007","unstructured":"Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ, Anidulafungin Study Group: Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007, 356: 2472-2482. 10.1056\/NEJMoa066906.","journal-title":"N Engl J Med"},{"key":"1601_CR23","volume-title":"Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard NCCLS document M27-A2","author":"National Committee for Clinical Laboratory Standards","year":"2002","unstructured":"National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard NCCLS document M27-A2. 2002, Wayne, PA: National Committee for Clinical Laboratory Standards"},{"key":"1601_CR24","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1128\/AAC.00420-08","volume":"52","author":"L Ostrosky-Zeichner","year":"2008","unstructured":"Ostrosky-Zeichner L, Rex JH, Pfaller MA, Diekema DJ, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ: Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob Agents Chemother. 2008, 52: 4175-4177. 10.1128\/AAC.00420-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"1601_CR25","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H: A new look at the statistical model identification. IEEE Trans Automat Contr. 1974, 19: 716-723. 10.1109\/TAC.1974.1100705.","journal-title":"IEEE Trans Automat Contr"},{"key":"1601_CR26","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1086\/520980","volume":"45","author":"PG Pappas","year":"2007","unstructured":"Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN: Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007, 45: 883-893. 10.1086\/520980.","journal-title":"Clin Infect Dis"},{"key":"1601_CR27","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1086\/374850","volume":"36","author":"JH Rex","year":"2003","unstructured":"Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, , , , , , National Institute of Allergy and Infectious Diseases Mycoses Study Group, et al: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003, 36: 1221-1228. 10.1086\/374850.","journal-title":"Clin Infect Dis"},{"key":"1601_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1586\/14787210.5.1.45","volume":"5","author":"P de la Torre","year":"2007","unstructured":"de la Torre P, Reboli AC: Anidulafungin: a new echinocandin for candidal infections. Expert Rev Anti Infect Ther. 2007, 5: 45-52. 10.1586\/14787210.5.1.45.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1601_CR29","first-page":"121","volume":"20","author":"A Espinel-Ingroff","year":"2003","unstructured":"Espinel-Ingroff A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003, 20: 121-136.","journal-title":"Rev Iberoam Micol"},{"key":"1601_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1469-0691.2001.00158.x","volume":"7","author":"CB Moore","year":"2001","unstructured":"Moore CB, Oakley KL, Denning DW: In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect. 2001, 7: 11-16.","journal-title":"Clin Microbiol Infect"},{"key":"1601_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ijantimicag.2010.02.020","volume":"36","author":"S Krishnan-Natesan","year":"2010","unstructured":"Krishnan-Natesan S, Cutright J, Manavathu EK, Alangaden GJ, Revankar S, Chandrasekar PH: A comparative study of the in vivo efficacy of anidulafungin, caspofungin and fluconazole on the early stage of infection in a neutropenic murine disseminated candidiasis infection model. Int J Antimicrob Agents. 2010, 36: 33-36. 10.1016\/j.ijantimicag.2010.02.020.","journal-title":"Int J Antimicrob Agents"},{"key":"1601_CR32","volume-title":"Proceedings of 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): 12-15 September 2009","author":"R Petraitiene","year":"2009","unstructured":"Petraitiene R, Petraitis V, Greene L, Cotton MP, Aghamolla T, Valdez JM, Bacher J, Walsh TJ: Efficacy of anidulafungin (AFG) vs. fluconazole (FLC) in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits: effects of early treatment (ERx) and delayed treatment (DRx). Proceedings of 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): 12-15 September 2009. 2009, San Francisco, CA. American Society for Microbiology"},{"key":"1601_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1128\/EC.00246-08","volume":"8","author":"B Hao","year":"2009","unstructured":"Hao B, Clancy CJ, Cheng S, Raman SB, Iczkowski KA, Nguyen MH: Candida albicans RFX2 encodes a DNA binding protein involved in DNA damage responses, morphogenesis, and virulence. Eukaryot Cell. 2009, 8: 627-639. 10.1128\/EC.00246-08.","journal-title":"Eukaryot Cell"},{"key":"1601_CR34","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2220\/biomedres.29.257","volume":"29","author":"S Hosogi","year":"2008","unstructured":"Hosogi S, Iwasaki Y, Yamada T, Komatani-Tamiya N, Hiramatsu A, Kohno Y, Ueda M, Arimoto T, Marunaka Y: Effect of inducible nitric oxide synthase on apoptosis in Candida-induced acute lung injury. Biomed Res. 2008, 29: 257-266. 10.2220\/biomedres.29.257.","journal-title":"Biomed Res"},{"key":"1601_CR35","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1128\/IAI.00159-06","volume":"74","author":"A Mullick","year":"2006","unstructured":"Mullick A, Leon Z, Min-Oo G, Berghout J, Lo R, Daniels E, Gros P: Cardiac failure in C5-deficient A\/J mice after Candida albicans infection. Infect Immun. 2006, 74: 4439-3351. 10.1128\/IAI.00159-06.","journal-title":"Infect Immun"},{"key":"1601_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1086\/430952","volume":"192","author":"B Spellberg","year":"2005","unstructured":"Spellberg B, Ibrahim AS, Edwards JE, Filler SG: Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis. 2005, 192: 336-343. 10.1086\/430952.","journal-title":"J Infect Dis"},{"key":"1601_CR37","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/intimm\/dxh177","volume":"16","author":"SG Correa","year":"2004","unstructured":"Correa SG, Rodr\u00edguez-Gal\u00e1n MC, Salido-Renter\u00eda B, Cano R, Cejas H, Sotomayor CE: High dissemination and hepatotoxicity in rats infected with Candida albicans after stress exposure: potential sensitization to liver damage. Int Immunol. 2004, 16: 1761-1768. 10.1093\/intimm\/dxh177.","journal-title":"Int Immunol"},{"key":"1601_CR38","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/clinids\/14.4.875","volume":"14","author":"JA Lecciones","year":"1992","unstructured":"Lecciones JA, Lee JW, Navarro E, Witebsky FG, Marshall D, Steinberg SM, Pizzo PA, Walsh TJ: Vascular catheter-associated fungemia in cancer patients: analysis of 155 episodes. Rev Infect Dis. 1992, 14: 875-883. 10.1093\/clinids\/14.4.875.","journal-title":"Rev Infect Dis"},{"key":"1601_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0732-8893(93)90020-8","volume":"17","author":"J Berenguer","year":"1993","unstructured":"Berenguer J, Buck M, Witebsky F, Stock F, Pizzo PA, Walsh TJ: Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis: disseminated versus single organ infection. Diagnostic Microbiol Infect Dis. 1993, 17: 103-109. 10.1016\/0732-8893(93)90020-8.","journal-title":"Diagnostic Microbiol Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-11-261\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T23:25:18Z","timestamp":1548199518000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-11-261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,30]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1601"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-11-261","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,30]]},"article-number":"261"}}